Bio-Rad Collaborates with Biodesix to Launch Blood-Based Immunoassay-Based Test to Detect Coronavirus Antibodies
By LabMedica International staff writers Posted on 28 May 2020 |
Image: BioRad QX200 Digital Droplet PCR System (Photo courtesy of Bio-Rad Laboratories, Inc.)
Bio-Rad Laboratories, Inc. (Hercules, CA, USA) has entered into a collaboration with Biodesix, Inc. (Boulder, CO, USA) to launch a blood-based immunoassay-based test that identifies antibodies to SARS-CoV-2.
After infection with SARS-CoV-2, viral antigens stimulate the body's adaptive immune system to produce antibodies to fight the virus. The Platelia SARS-CoV-2 Total Ab test identifies if a patient has produced those antibodies. The test can be utilized in combination with the SARS-CoV-2 Droplet Digital PCR (ddPCR) test to diagnose symptomatic patients and assess immunity in the population.
The Platelia SARS-CoV-2 Total Ab test was granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) late last month, making it the first total antibody test to receive EUA from the FDA. Clinical evaluation demonstrated specificity greater than 99% and diagnostic sensitivity of 98% eight days after the onset of symptoms. Cross-reactivity testing demonstrated specificity of 100% with no reactivity against other interfering specimens, including non-CoV-2 coronaviruses.
“The Platelia SARS-CoV-2 Total Ab test helps clinicians determine if a patient has potentially been infected by SARS-CoV-2 and therefore has developed an immune response against the virus,” said Scott Hutton, Chief Executive Officer of Biodesix. “This gives us a more complete understanding of infection rates as well as potential immunity, which will be vital information as we continue working to stop the spread of COVID-19.”
After infection with SARS-CoV-2, viral antigens stimulate the body's adaptive immune system to produce antibodies to fight the virus. The Platelia SARS-CoV-2 Total Ab test identifies if a patient has produced those antibodies. The test can be utilized in combination with the SARS-CoV-2 Droplet Digital PCR (ddPCR) test to diagnose symptomatic patients and assess immunity in the population.
The Platelia SARS-CoV-2 Total Ab test was granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) late last month, making it the first total antibody test to receive EUA from the FDA. Clinical evaluation demonstrated specificity greater than 99% and diagnostic sensitivity of 98% eight days after the onset of symptoms. Cross-reactivity testing demonstrated specificity of 100% with no reactivity against other interfering specimens, including non-CoV-2 coronaviruses.
“The Platelia SARS-CoV-2 Total Ab test helps clinicians determine if a patient has potentially been infected by SARS-CoV-2 and therefore has developed an immune response against the virus,” said Scott Hutton, Chief Executive Officer of Biodesix. “This gives us a more complete understanding of infection rates as well as potential immunity, which will be vital information as we continue working to stop the spread of COVID-19.”
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants